Cargando…
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic
As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C vir...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283245/ https://www.ncbi.nlm.nih.gov/pubmed/32518317 http://dx.doi.org/10.1038/s41598-020-66440-9 |